Edition:
India

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

146.86USD
16 Jan 2018
Change (% chg)

$1.10 (+0.75%)
Prev Close
$145.76
Open
$146.22
Day's High
$148.06
Day's Low
$146.07
Volume
2,825,223
Avg. Vol
1,896,067
52-wk High
$148.06
52-wk Low
$110.76

Latest Key Developments (Source: Significant Developments)

Novartis says data reinforces ‍Cosentyx effectiveness
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Novartis AG ::NOVARTIS NEW DATA REINFORCES SUPERIORITY OF COSENTYX® VERSUS STELARA®* IN ACHIEVING SKIN CLEARANCE FOR PSORIASIS PATIENTS.‍CLARITY STUDY SHOW COSENTYX(®) (SECUKINUMAB) WAS SIGNIFICANTLY MORE EFFECTIVE THAN STELARA(®*) (USTEKINUMAB) IN DELIVERING CLEAR AND ALMOST CLEAR SKIN AT 12 WEEKS AND AT 16 WEEKS​.‍COSENTYX CONTINUED TO HAVE A FAVORABLE AND CONSISTENT SAFETY PROFILE​.  Full Article

Halozyme Projects 25 To 30 Percent Enhanze Royalty Growth In 2018
Wednesday, 10 Jan 2018 

Jan 9 (Reuters) - Halozyme Therapeutics Inc ::HALOZYME PROJECTS 25 TO 30 PERCENT ENHANZE ROYALTY GROWTH IN 2018.HALOZYME THERAPEUTICS INC - ‍ FORECASTS POTENTIAL ROYALTY REVENUE FOR ENHANZE TO REACH NEARLY $1 BILLION IN 2027 ​.HALOZYME THERAPEUTICS INC - ‍EXPECTS ADDITIONAL PARTNERS TO BEGIN THREE PHASE 1 STUDIES WITH NEW TARGETS FOR ENHANZE​ IN 2018.  Full Article

Geron-Latest Time For Janssen Continuation Decision To Continue Development Of Imetelstat In Any Indication Expected By Q4 2018/Q1 2019
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Geron Corp ::GERON -LATEST TIME FOR JANSSEN CONTINUATION DECISION TO CONTINUE DEVELOPMENT OF IMETELSTAT IN ANY INDICATION EXPECTED BY Q4 2018/Q1 2019 - SEC FILING‍​.  Full Article

Landmark Schizophrenia Data Receive FDA Approval For Inclusion In Invega Sustenna (Paliperidone Palmitate) Label
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Johnson & Johnson ::LANDMARK SCHIZOPHRENIA DATA THAT BRING HOPE IN BREAKING THE CYCLE OF HOSPITALIZATION AND INCARCERATION RECEIVE FDA APPROVAL FOR INCLUSION IN INVEGA SUSTENNA® (PALIPERIDONE PALMITATE) LABEL.JANSSEN PHARMACEUTICALS SAYS INVEGA SUSTENNA IS THE FIRST ANTIPSYCHOTIC TO HAVE U.S. FDA APPROVE INCLUSION OF REAL-WORLD DATA IN ITS PRODUCT LABELING.  Full Article

FDA Issues Class I Recall Of Reprocessed Agilis Steerable Introducer Sheath By Sterilmed
Wednesday, 3 Jan 2018 

Jan 2 (Reuters) - U.S. Food And Drug Administration::U.S. FOOD AND DRUG ADMINISTRATION SAYS ISSUES CLASS I RECALL OF THE REPROCESSED AGILIS STEERABLE INTRODUCER SHEATH BY STERILMED.U.S. FDA SAYS THE AGILIS STEERABLE INTRODUCER SHEATH’S HEMOSTATIC VALVE MAY FAIL DUE TO AN IMPROPER SEAL OF THE SHEATH HUB.U.S. FDA SAYS USE OF THE AFFECTED PRODUCTS BY STERILMED MAY CAUSE "SERIOUS HEALTH CONSEQUENCES" FOR PATIENTS, INCLUDING DEATH.  Full Article

Syros Announces Clinical Supply Agreement With Janssen To Evaluate SY-1425
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Syros Pharmaceuticals Inc ::SYROS ANNOUNCES CLINICAL SUPPLY AGREEMENT WITH JANSSEN TO EVALUATE SY-1425, ITS FIRST-IN-CLASS SELECTIVE RARΑ AGONIST, IN COMBINATION WITH DARATUMUMAB IN GENOMICALLY DEFINED AML AND MDS PATIENTS.SYROS PHARMACEUTICALS - JANSSEN TO SUPPLY DARATUMUMAB FOR COMBINATION DOSING COHORT IN SYROS' ONGOING PHASE 2 CLINICAL TRIAL OF SY-1425.SYROS PHARMACEUTICALS - JANSSEN TO RECEIVE ACCESS TO DATA FROM COHORT EVALUATING SAFETY & EFFICACY OF SY-1425 IN COMBINATION WITH DARATUMUMAB FOR RESEARCH AND DEVELOPMENT.SYROS PHARMACEUTICALS - ‍EXPECTS TO BEGIN ENROLLING PATIENTS IN COMBINATION COHORT WITH DARATUMUMAB IN EARLY 2018​.  Full Article

Johnson & Johnson Declares Cash Dividend For Q1 2018 Of $0.84 Per Share On Co's Common Stock
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Johnson & Johnson ::JOHNSON & JOHNSON ANNOUNCES QUARTERLY DIVIDEND FOR FIRST QUARTER 2018.J&J - BOARD OF DIRECTORS HAS DECLARED A CASH DIVIDEND FOR Q1 OF 2018 OF $0.84 PER SHARE ON COMPANY'S COMMON STOCK.  Full Article

Genscript Biotech Says US, Ireland Units ‍& Janssen Biotech Enter Collaboration & License Agreement ​
Friday, 22 Dec 2017 

Dec 22 (Reuters) - Genscript Biotech Corp <1548.HK>::US, IRELAND UNITS ‍& JANSSEN BIOTECH ENTER COLLABORATION & LICENSE AGREEMENT TO DEVELOP MULTIPLE MYELOMA PRODUCTS ​.‍ACCORDING TO DEAL , JANSSEN SHALL UPFRONT PAYMENTS OF US$350 MILLION TO UNIT FOR RIGHTS GRANTED​.  Full Article

Janssen Enters Collaboration And License Agreement With China's Legend Biotech To Develop CAR-T Cancer Therapy
Friday, 22 Dec 2017 

Dec 21 (Reuters) - Johnson & Johnson ::JANSSEN ENTERS WORLDWIDE COLLABORATION AND LICENSE AGREEMENT WITH CHINESE COMPANY LEGEND BIOTECH TO DEVELOP INVESTIGATIONAL CAR-T ANTI-CANCER THERAPY.JANSSEN BIOTECH - J&J REAFFIRMS FY 2017 ADJUSTED EARNINGS PER SHARE GUIDANCE OF $7.25 - $7.30.FY2017 EARNINGS PER SHARE VIEW $7.28 -- THOMSON REUTERS I/B/E/S.JANSSEN - ENTERED INTO WORLDWIDE COLLABORATION, LICENSE DEAL WITH UNITS OF GENSCRIPT BIOTECH CORPORATION.JANSSEN SAYS UNDER AGREEMENT, IT WILL MAKE AN UPFRONT PAYMENT OF $350 MILLION THAT WILL BE RECORDED IN Q4.JANSSEN SAYS COS ENTERED INTO A 50/50% COST-SHARING/PROFIT-SPLIT ARRANGEMENT, EXCEPT IN GREATER CHINA.JANSSEN SAYS IN GREATER CHINA, JANSSEN AND LEGEND HAVE A 30/70 PERCENT COST-SHARING/PROFIT-SPLIT ARRANGEMENT.  Full Article

Janssen Submits Supplemental NDA To FDA Seeking New Indications For Xarelto
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Johnson & Johnson ::JANSSEN SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO FDA SEEKING NEW INDICATIONS FOR XARELTO® (RIVAROXABAN) FOR PATIENTS WITH CHRONIC CORONARY AND/OR PERIPHERAL ARTERY DISEASE (CAD/PAD).JANSSEN SUBMITS SUPPLEMENTAL NDA TO FDA SEEKING NEW INDICATIONS FOR XARELTO FOR PATIENTS WITH CHRONIC CORONARY AND/OR PERIPHERAL ARTERY DISEASE.  Full Article

Photo

Bayer, J&J win reversal of $28 million verdict in Xarelto lawsuit

A Pennsylvania state court judge on Tuesday overturned a $27.8 million jury award to an Indiana couple who accused Bayer AG and Johnson & Johnson of failing to warn of internal bleeding risks of their drug Xarelto, the companies said.